Lurbinectedin Shows Modest Efficacy and Safety in ES-SCLC
Lurbinectedin in ES-SCLC: Current Landscape and Future Horizons The landscape of extensive-stage small cell lung cancer (ES-SCLC) treatment is constantly evolving. A recent study, published in the European Journal of Cancer, sheds light on the real-world efficacy and safety of lurbinectedin, a drug showing promise in this challenging disease. As a seasoned healthcare journalist, I’ve … Read more